As of 2024-12-14, the EV/EBITDA ratio of Apellis Pharmaceuticals Inc (APLS) is -18.87. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Apellis's latest enterprise value is 4,183.89 mil USD. Apellis's TTM EBITDA according to its financial statements is -221.69 mil USD. Dividing these 2 quantities gives us the above Apellis EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.8x - 15.9x | 14.8x |
| Forward P/E multiples | 15.0x - 15.5x | 15.2x |
| Fair Price | (27.18) - (28.07) | (27.27) |
| Upside | -181.9% - -184.6% | -182.2% |
| Date | EV/EBITDA |
| 2024-11-29 | -19.29 |
| 2024-11-27 | -19.41 |
| 2024-11-26 | -18.56 |
| 2024-11-25 | -18.15 |
| 2024-11-22 | -17.51 |
| 2024-11-21 | -15.82 |
| 2024-11-20 | -15.67 |
| 2024-11-19 | -16.52 |
| 2024-11-18 | -14.94 |
| 2024-11-15 | -14.99 |
| 2024-11-14 | -15.99 |
| 2024-11-13 | -16.10 |
| 2024-11-12 | -16.67 |
| 2024-11-11 | -16.85 |
| 2024-11-08 | -17.07 |
| 2024-11-07 | -16.38 |
| 2024-11-06 | -16.43 |
| 2024-11-05 | -16.00 |
| 2024-11-04 | -16.27 |
| 2024-11-01 | -15.95 |
| 2024-10-31 | -15.55 |
| 2024-10-30 | -15.80 |
| 2024-10-29 | -15.63 |
| 2024-10-28 | -15.59 |
| 2024-10-25 | -15.22 |
| 2024-10-24 | -15.72 |
| 2024-10-23 | -15.39 |
| 2024-10-22 | -15.74 |
| 2024-10-21 | -15.33 |
| 2024-10-18 | -15.96 |
| 2024-10-17 | -15.92 |
| 2024-10-16 | -15.93 |
| 2024-10-15 | -15.93 |
| 2024-10-14 | -15.61 |
| 2024-10-11 | -15.48 |
| 2024-10-10 | -15.21 |
| 2024-10-09 | -15.34 |
| 2024-10-08 | -15.62 |
| 2024-10-07 | -15.65 |
| 2024-10-04 | -15.69 |
| 2024-10-03 | -15.99 |
| 2024-10-02 | -16.23 |
| 2024-10-01 | -15.81 |
| 2024-09-30 | -16.43 |
| 2024-09-27 | -16.79 |
| 2024-09-26 | -17.00 |
| 2024-09-25 | -17.41 |
| 2024-09-24 | -17.50 |
| 2024-09-23 | -18.61 |
| 2024-09-20 | -18.49 |